A 61-year-old man with alcoholic cirrhosis presents with increasing abdominal distension. Examination reveals shifting dullness and a fluid thrill. Diagnostic ascitic tap shows: white cell count 180 cells/mm³ (neutrophils 35%), protein 18 g/L, albumin 8 g/L, lactate dehydrogenase 45 U/L, and glucose 4.8 mmol/L. His serum albumin is 28 g/L. The serum-ascites albumin gradient (SAAG) is 20 g/L. What does this ascitic fluid analysis indicate?
Q42
A 39-year-old woman with ulcerative colitis affecting the entire colon has been in remission on azathioprine 2 mg/kg/day for 3 years. She now wishes to conceive and seeks advice about her medication. Her thiopurine methyltransferase (TPMT) activity was normal before starting azathioprine. What is the most appropriate advice regarding her azathioprine therapy?
Q43
A 48-year-old man presents with a 6-month history of intermittent epigastric pain and bloating. He reports that the pain is worse after fatty meals. Upper GI endoscopy is normal. An ultrasound scan shows multiple small gallstones in the gallbladder but no bile duct dilatation. Liver function tests and amylase are normal. A hepatobiliary iminodiacetic acid (HIDA) scan shows a gallbladder ejection fraction of 22% (normal >35%) after cholecystokinin stimulation. What is the most likely diagnosis?
Q44
A 55-year-old woman with primary biliary cholangitis presents for review. She has been taking ursodeoxycholic acid 15 mg/kg/day for 18 months. Her alkaline phosphatase (ALP) has decreased from 420 U/L to 310 U/L (normal range 30-130 U/L), and her bilirubin remains normal at 12 μmol/L. She reports persistent pruritus affecting her quality of life despite antihistamines. What is the most appropriate next step in management?
Q45
A 42-year-old man with known Crohn's disease presents with chronic diarrhoea, weight loss, and a low serum vitamin B12 level. His disease has previously affected the terminal ileum, which was resected 3 years ago (50 cm resection). He now has steatorrhoea and a positive SeHCAT scan showing 7-day retention of 8%. What is the primary mechanism responsible for his steatorrhoea?
Q46
A 68-year-old woman with a history of non-steroidal anti-inflammatory drug (NSAID) use for osteoarthritis presents with coffee-ground vomiting. She is haemodynamically stable with a heart rate of 88 bpm and blood pressure of 135/82 mmHg. Her haemoglobin is 108 g/L (baseline 125 g/L). She takes amlodipine for hypertension. Upper GI endoscopy shows a 1.5 cm gastric ulcer with a clean base. What is the most appropriate management after endoscopy?
Q47
A 47-year-old woman presents with a 5-day history of severe epigastric pain radiating to the back, nausea, and vomiting. CT abdomen shows pancreatic oedema and peripancreatic fat stranding consistent with acute pancreatitis. Amylase is 1680 U/L. She has no history of alcohol use. Liver function tests show bilirubin 48 μmol/L, ALT 420 U/L, ALP 180 U/L. Abdominal ultrasound shows multiple gallstones and a dilated common bile duct measuring 9 mm. MRCP confirms a 6 mm stone in the distal common bile duct. Her CRP is 220 mg/L and she remains systemically unwell 72 hours after admission despite supportive management. What is the most appropriate management of the biliary obstruction?
Q48
A 52-year-old man with alcohol-related cirrhosis is admitted with confusion. He is drowsy but rousable, disorientated to time and place, and has a coarse flapping tremor. Serum ammonia is elevated at 95 μmol/L (normal 11-32). He is commenced on lactulose. The mechanism by which lactulose reduces hepatic encephalopathy is primarily through which of the following?
Q49
A 34-year-old woman presents with a 12-month history of crampy lower abdominal pain, abdominal distension, and loose stools up to 5 times daily. Symptoms are worse with stress and during menstruation. She has tried dietary modification without benefit. Examination and routine blood tests including coeliac serology are normal. She is diagnosed with IBS-D (diarrhoea predominant). First-line loperamide has provided minimal relief. What is the most appropriate pharmacological treatment?
Q50
A 45-year-old woman presents with burning retrosternal discomfort after meals and occasional regurgitation. She has been taking lansoprazole 30 mg daily for 3 months with minimal improvement. She has no dysphagia or weight loss. Upper GI endoscopy shows Los Angeles grade A oesophagitis and a 2 cm hiatus hernia. H. pylori rapid urease test is negative. What is the most appropriate next step in management?
Gastroenterology & Hepatology UK Medical PG Practice Questions and MCQs
Question 41: A 61-year-old man with alcoholic cirrhosis presents with increasing abdominal distension. Examination reveals shifting dullness and a fluid thrill. Diagnostic ascitic tap shows: white cell count 180 cells/mm³ (neutrophils 35%), protein 18 g/L, albumin 8 g/L, lactate dehydrogenase 45 U/L, and glucose 4.8 mmol/L. His serum albumin is 28 g/L. The serum-ascites albumin gradient (SAAG) is 20 g/L. What does this ascitic fluid analysis indicate?
A. Uncomplicated cirrhotic ascites with low risk of spontaneous bacterial peritonitis (Correct Answer)
B. Spontaneous bacterial peritonitis requiring immediate antibiotic therapy
C. Malignant ascites requiring cytological examination
D. Secondary bacterial peritonitis suggesting bowel perforation
E. Tuberculous peritonitis requiring anti-tuberculous therapy
Explanation: ***Uncomplicated cirrhotic ascites with low risk of spontaneous bacterial peritonitis***- The **SAAG of 20 g/L** (≥11 g/L) confirms **portal hypertension** due to cirrhosis as the underlying cause of the ascites.- The **absolute neutrophil count (ANC)** is only **63 cells/mm³** (35% of 180), which is well below the **250 cells/mm³** threshold required to diagnose **spontaneous bacterial peritonitis (SBP)**.*Spontaneous bacterial peritonitis requiring immediate antibiotic therapy*- **SBP** is diagnosed when the ascitic fluid **polymorphonuclear (PMN) count** is **≥250 cells/mm³**, whereas this patient's count is significantly lower (63 cells/mm³).- While a low ascitic **protein (18 g/L)** is a risk factor for future SBP, it does not confirm an active infection without elevated neutrophils.*Malignant ascites requiring cytological examination*- **Malignant ascites** typically presents with a **low SAAG (<11 g/L)** and a **high protein content (>25 g/L)** due to increased capillary permeability.- This patient's **SAAG of 20 g/L** and low protein are characteristic of a **transudative process** related to portal hypertension, not malignancy.*Secondary bacterial peritonitis suggesting bowel perforation*- **Secondary peritonitis** is characterized by an **ANC >250 cells/mm³**, ascitic **glucose <2.8 mmol/L**, and typically elevated **LDH**.- The normal **glucose (4.8 mmol/L)** and low **LDH (45 U/L)** in this patient rule out a surgical emergency like **bowel perforation**.*Tuberculous peritonitis requiring anti-tuberculous therapy*- **Tuberculous peritonitis** typically presents with a **low SAAG (<11 g/L)** and a high total protein concentration.- The white cell differential in TB usually shows a **lymphocytic predominance**, which is not consistent with the 35% neutrophil count and high SAAG seen here.
Question 42: A 39-year-old woman with ulcerative colitis affecting the entire colon has been in remission on azathioprine 2 mg/kg/day for 3 years. She now wishes to conceive and seeks advice about her medication. Her thiopurine methyltransferase (TPMT) activity was normal before starting azathioprine. What is the most appropriate advice regarding her azathioprine therapy?
A. Continue azathioprine throughout pregnancy as benefits outweigh risks (Correct Answer)
B. Switch to mesalazine before conception and discontinue azathioprine
C. Stop azathioprine 3 months before attempting conception
D. Switch to methotrexate as it is safer in pregnancy
E. Reduce azathioprine dose to 1 mg/kg/day during pregnancy
Explanation: ***Continue azathioprine throughout pregnancy as benefits outweigh risks***
- Maintaining **disease remission** is the priority during pregnancy, as active **Ulcerative Colitis** significantly increases the risk of **preterm birth** and **low birth weight**.
- Azathioprine is considered **compatible with pregnancy** by major guidelines (e.g., ECCO, BSG), as the well-established risks of a maternal disease flare far outweigh the theoretical risks of the medication.
*Switch to mesalazine before conception and discontinue azathioprine*
- **Mesalazine** is generally insufficient to maintain remission in patients who have extensive colitis and require **thiopurines** for disease control.
- Changing a stable, effective maintenance therapy just before or during pregnancy significantly increases the **risk of disease relapse**, which is detrimental to both mother and fetus.
*Stop azathioprine 3 months before attempting conception*
- Discontinuing effective maintenance therapy in a patient with extensive ulcerative colitis will likely lead to **disease flare-ups**, which pose greater risks to pregnancy outcomes than continued azathioprine.
- Current clinical evidence and expert guidelines do not support the need to stop **thiopurines** during the preconception period or throughout pregnancy.
*Switch to methotrexate as it is safer in pregnancy*
- **Methotrexate** is a potent **teratogen** (Category X) and is strictly **contraindicated** in pregnancy due to its high risk of major fetal malformations and pregnancy loss.
- Patients must stop methotrexate at least **3 to 6 months before conception** and be on high-dose folic acid to clear it from their system.
*Reduce azathioprine dose to 1 mg/kg/day during pregnancy*
- There is no clinical evidence to suggest that an empiric **dose reduction** of azathioprine improves neonatal outcomes; instead, it increases the risk of maternal **disease flare**.
- Optimal management involves close monitoring of **thiopurine metabolite levels** and **TPMT activity** to ensure therapeutic efficacy and safety rather than arbitrary dose adjustments.
Question 43: A 48-year-old man presents with a 6-month history of intermittent epigastric pain and bloating. He reports that the pain is worse after fatty meals. Upper GI endoscopy is normal. An ultrasound scan shows multiple small gallstones in the gallbladder but no bile duct dilatation. Liver function tests and amylase are normal. A hepatobiliary iminodiacetic acid (HIDA) scan shows a gallbladder ejection fraction of 22% (normal >35%) after cholecystokinin stimulation. What is the most likely diagnosis?
A. Functional dyspepsia
B. Biliary dyskinesia (Correct Answer)
C. Chronic acalculous cholecystitis
D. Sphincter of Oddi dysfunction
E. Gallstone-related biliary colic
Explanation: ***Biliary dyskinesia***- This condition is characterized by **biliary-type pain** in the presence of impaired gallbladder emptying, confirmed by a **HIDA scan** showing an **ejection fraction (EF) of 22%** (normal >35%) after **cholecystokinin (CCK) stimulation**.- The symptoms of intermittent epigastric pain and bloating, worse after fatty meals, are consistent with gallbladder dysfunction despite the presence of small gallstones, as the primary issue is reduced motility.*Functional dyspepsia*- This is a diagnosis of exclusion, typically considered when **upper GI endoscopy** is normal and there are no objective structural or functional abnormalities.- The presence of a significantly reduced gallbladder ejection fraction on HIDA scan indicates a clear objective functional abnormality, ruling out functional dyspepsia.*Chronic acalculous cholecystitis*- This diagnosis refers to chronic gallbladder inflammation **without the presence of gallstones**.- The patient's ultrasound explicitly shows **multiple small gallstones** in the gallbladder, directly contradicting the
Question 44: A 55-year-old woman with primary biliary cholangitis presents for review. She has been taking ursodeoxycholic acid 15 mg/kg/day for 18 months. Her alkaline phosphatase (ALP) has decreased from 420 U/L to 310 U/L (normal range 30-130 U/L), and her bilirubin remains normal at 12 μmol/L. She reports persistent pruritus affecting her quality of life despite antihistamines. What is the most appropriate next step in management?
A. Add bezafibrate to ursodeoxycholic acid therapy
B. Increase ursodeoxycholic acid dose to 20 mg/kg/day
C. Add rifampicin for symptomatic relief of pruritus (Correct Answer)
D. Refer for liver transplant assessment
E. Switch from ursodeoxycholic acid to obeticholic acid monotherapy
Explanation: ***Add rifampicin for symptomatic relief of pruritus***- In patients with **Primary Biliary Cholangitis (PBC)**, pruritus that remains refractory to first-line agents like **cholestyramine** or antihistamines is managed with **rifampicin**.- **Rifampicin** acts as a **pregname X receptor (PXR)** agonist, inducing hepatic enzymes that modify bile acid metabolism to reduce itch-inducing substances.*Add bezafibrate to ursodeoxycholic acid therapy*- **Bezafibrate** is a second-line treatment used specifically for patients with an **inadequate biochemical response** to UDCA (e.g., elevated ALP).- While it can help with pruritus, the clinical priority here is the failure of first-line symptomatic relief, for which **rifampicin** is the better-established second-line choice for itch.*Increase ursodeoxycholic acid dose to 20 mg/kg/day*- The therapeutic dosage for **UDCA** in PBC is strictly established at **13–15 mg/kg/day**.- Increasing the dose to **20 mg/kg/day** does not provide additional clinical benefit and does not specifically address the **symptomatic pruritus**.*Refer for liver transplant assessment*- Liver transplant is indicated for **end-stage liver disease**, characterized by high **bilirubin** (typically >50 μmol/L) or signs of **decompensation**.- This patient has a normal **bilirubin** of 12 μmol/L and no evidence of cirrhosis or liver failure, making a referral premature.*Switch from ursodeoxycholic acid to obeticholic acid monotherapy*- **Obeticholic acid** is typically used as an **add-on therapy** to UDCA rather than a monotherapy switch when biochemical goals are not met.- Notably, obeticholic acid can actually **exacerbate pruritus** as a common side effect, which would worsen this patient's primary complaint.
Question 45: A 42-year-old man with known Crohn's disease presents with chronic diarrhoea, weight loss, and a low serum vitamin B12 level. His disease has previously affected the terminal ileum, which was resected 3 years ago (50 cm resection). He now has steatorrhoea and a positive SeHCAT scan showing 7-day retention of 8%. What is the primary mechanism responsible for his steatorrhoea?
A. Bacterial overgrowth in the small intestine due to altered anatomy
B. Pancreatic exocrine insufficiency secondary to chronic inflammation
C. Bile acid malabsorption causing colonic secretion and fat malabsorption (Correct Answer)
D. Active Crohn's disease in the remaining small bowel causing malabsorption
E. Intestinal lymphangiectasia causing protein-losing enteropathy
Explanation: ***Bile acid malabsorption causing colonic secretion and fat malabsorption***- This patient's **50 cm terminal ileal resection** is a critical factor, as the terminal ileum is where **bile acids** are primarily reabsorbed in the **enterohepatic circulation**.- The **positive SeHCAT scan (8% retention)** directly confirms severe **bile acid malabsorption**, which leads to a depleted bile acid pool, impairing fat emulsification and causing **steatorrhoea**, and excess bile acids in the colon driving secretory diarrhoea.*Bacterial overgrowth in the small intestine due to altered anatomy*- While surgical resection in Crohn's can predispose to **small intestinal bacterial overgrowth (SIBO)** by altering gut anatomy or motility, the direct evidence of **bile acid malabsorption** (SeHCAT scan) points to a more specific cause for steatorrhoea.- SIBO can cause malabsorption and diarrhoea, partly by deconjugating bile acids, but the primary pathology here is the *loss* of bile acids from the enterohepatic circulation due to resection, not just deconjugation.*Pancreatic exocrine insufficiency secondary to chronic inflammation*- There is no clinical evidence in the patient's presentation (e.g., recurrent pancreatitis, abdominal pain radiating to the back) to suggest **pancreatic exocrine insufficiency**.- This condition would lead to generalized maldigestion of fats, proteins, and carbohydrates, and would be typically diagnosed by tests like a **fecal elastase** level, not a SeHCAT scan.*Active Crohn's disease in the remaining small bowel causing malabsorption*- While **active Crohn's disease** can cause malabsorption, the patient's history includes a **terminal ileal resection**, which provides a more direct and specific explanation for the **steatorrhoea** and **vitamin B12 deficiency**.- The symptoms are more consistent with the functional consequences of resected terminal ileum rather than active inflammation, although inflammation could coexist. The SeHCAT test specifically points to bile acid issue.*Intestinal lymphangiectasia causing protein-losing enteropathy*- **Intestinal lymphangiectasia** is a rare disorder characterized by dilated lymphatic vessels, leading to **protein-losing enteropathy**, typically presenting with **oedema**, chylous effusions, and profound hypoalbuminemia.- This patient's symptoms (steatorrhoea, low B12, positive SeHCAT) are not characteristic of intestinal lymphangiectasia, which primarily affects lymphatic drainage and protein absorption, not bile acid reabsorption.
Question 46: A 68-year-old woman with a history of non-steroidal anti-inflammatory drug (NSAID) use for osteoarthritis presents with coffee-ground vomiting. She is haemodynamically stable with a heart rate of 88 bpm and blood pressure of 135/82 mmHg. Her haemoglobin is 108 g/L (baseline 125 g/L). She takes amlodipine for hypertension. Upper GI endoscopy shows a 1.5 cm gastric ulcer with a clean base. What is the most appropriate management after endoscopy?
A. Discharge with oral proton pump inhibitor therapy and H. pylori eradication if positive (Correct Answer)
B. Continue intravenous proton pump inhibitor infusion for 72 hours then switch to oral therapy
C. Arrange repeat endoscopy in 24 hours to reassess ulcer
D. Start intravenous proton pump inhibitor twice daily for 72 hours as an inpatient
E. Discharge immediately on oral proton pump inhibitor therapy without further testing
Explanation: ***Discharge with oral proton pump inhibitor therapy and H. pylori eradication if positive***- A gastric ulcer with a **clean base** is classified as **Forrest III**, which carries a very low risk of rebleeding (<5%) and can be managed in an outpatient setting.- Since the patient is **haemodynamically stable** and lacks high-risk endoscopic stigmata, early discharge on **oral PPIs** is the standard of care to prevent recurrence.*Continue intravenous proton pump inhibitor infusion for 72 hours then switch to oral therapy*- **Intravenous PPI infusions** are reserved for patients with high-risk stigmata, such as **active spurting** (Forrest Ia) or a **visible vessel** (Forrest IIa).- Clean-based ulcers do not derive additional benefit from IV over **oral PPI** therapy, making prolonged infusion unnecessary and costly.*Arrange repeat endoscopy in 24 hours to reassess ulcer*- Routine **repeat endoscopy** within 24 hours is not indicated for stable patients with low-risk findings like a **clean-based ulcer**.- Surveillance endoscopy is typically only indicated if there is evidence of **clinical rebleeding** or to ensure gastric ulcer healing after 6-8 weeks.*Start intravenous proton pump inhibitor twice daily for 72 hours as an inpatient*- This approach is indicated for high-risk patients who have undergone **endoscopic haemostasis** to prevent rebleeding.- For a **Forrest III** lesion, inpatient status for the sole purpose of IV medication is inappropriate as the risk of mortality and rebleeding is extremely low.*Discharge immediately on oral proton pump inhibitor therapy without further testing*- While discharge and PPI therapy are correct, all patients with peptic ulcers must be tested for **H. pylori infection** and treated if positive.- Neglecting to test for and eradicate **H. pylori** significantly increases the risk of future **ulcer recurrence** and complications.
Question 47: A 47-year-old woman presents with a 5-day history of severe epigastric pain radiating to the back, nausea, and vomiting. CT abdomen shows pancreatic oedema and peripancreatic fat stranding consistent with acute pancreatitis. Amylase is 1680 U/L. She has no history of alcohol use. Liver function tests show bilirubin 48 μmol/L, ALT 420 U/L, ALP 180 U/L. Abdominal ultrasound shows multiple gallstones and a dilated common bile duct measuring 9 mm. MRCP confirms a 6 mm stone in the distal common bile duct. Her CRP is 220 mg/L and she remains systemically unwell 72 hours after admission despite supportive management. What is the most appropriate management of the biliary obstruction?
A. Urgent ERCP within 24 hours of admission
B. Early ERCP within 72 hours of admission (Correct Answer)
C. ERCP after clinical improvement and inflammatory markers normalize
D. Proceed directly to laparoscopic cholecystectomy with intraoperative cholangiography and bile duct exploration
E. Conservative management with antibiotics and delayed elective ERCP in 6 weeks
Explanation: ***Early ERCP within 72 hours of admission***- In cases of **gallstone pancreatitis** with persistent **biliary obstruction** (dilated CBD, elevated LFTs, MRCP confirmed stone), **ERCP** should be performed within 72 hours to remove the obstructing stone.- This patient has a confirmed **6 mm stone** in the distal common bile duct and remains systemically unwell after 72 hours, indicating that the obstruction has not resolved spontaneously and requires intervention.*Urgent ERCP within 24 hours of admission*- **Urgent ERCP (within 24 hours)** is strictly indicated for **gallstone pancreatitis** complicated by concurrent **acute cholangitis** (fever, jaundice, RUQ pain) or severe sepsis related to biliary obstruction.- While the patient has elevated bilirubin and is unwell, the absence of classic signs of acute cholangitis (e.g., fever, chills, hypotension) means intervention within 24 hours is not immediately mandatory.*ERCP after clinical improvement and inflammatory markers normalize*- Waiting for clinical improvement and normalization of inflammatory markers is inappropriate when there is imaging proof of **persistent biliary obstruction** (CBD stone) and the patient remains unwell.- Delaying intervention in the presence of a known **CBD stone** carries a high risk of worsening pancreatitis, developing **ascending cholangitis**, or other severe biliary complications.*Proceed directly to laparoscopic cholecystectomy with intraoperative cholangiography and bile duct exploration*- **Laparoscopic cholecystectomy** is recommended during the same admission for gallstone pancreatitis, but only after the **acute pancreatitis** has resolved and the CBD has been cleared.- Attempting **bile duct exploration** or cholecystectomy during the acute inflammatory phase of pancreatitis is associated with a significantly higher risk of morbidity and complications compared to pre-operative **ERCP** for stone clearance.*Conservative management with antibiotics and delayed elective ERCP in 6 weeks*- **Conservative management** with antibiotics is unsuitable for **persistent biliary obstruction** as it does not address the mechanical blockage caused by the stone.- A 6-week delay for **elective ERCP** in a patient with active pancreatitis and confirmed **CBD obstruction** is dangerous and would likely lead to recurrent attacks, **cholangitis**, or other severe complications.
Question 48: A 52-year-old man with alcohol-related cirrhosis is admitted with confusion. He is drowsy but rousable, disorientated to time and place, and has a coarse flapping tremor. Serum ammonia is elevated at 95 μmol/L (normal 11-32). He is commenced on lactulose. The mechanism by which lactulose reduces hepatic encephalopathy is primarily through which of the following?
A. Inhibition of glutaminase enzyme in enterocytes
B. Binding of ammonia in the intestinal lumen preventing absorption
C. Acidification of colonic contents leading to conversion of ammonia to non-absorbable ammonium ions (Correct Answer)
D. Direct reduction of ammonia-producing bacteria in the colon
E. Promotion of ammonia excretion through increased renal clearance
Explanation: ***Acidification of colonic contents leading to conversion of ammonia to non-absorbable ammonium ions***
- Lactulose is metabolized by **colonic bacteria** into **organic acids** (lactic and acetic acids), which significantly **lowers the colonic pH**.
- This acidic environment promotes the conversion of diffusable, absorbable **ammonia (NH3)** into non-absorbable **ammonium ions (NH4+)**, which are then **trapped in the colon** and excreted in feces.
*Inhibition of glutaminase enzyme in enterocytes*
- Lactulose does not directly inhibit the **glutaminase enzyme** in enterocytes, which converts glutamine to ammonia.
- While glutamine metabolism is a source of ammonia, this is not the primary mechanism of action for **lactulose**.
*Binding of ammonia in the intestinal lumen preventing absorption*
- Lactulose does not act as an **ammonia binder** or chelating agent in the intestinal lumen.
- Its mechanism relies on changing the chemical state of ammonia via **pH modification** (ion trapping), not physical binding.
*Direct reduction of ammonia-producing bacteria in the colon*
- Lactulose is a synthetic disaccharide that alters gut flora but is not a **direct antibiotic** targeting ammonia-producing bacteria.
- This specific mechanism is primarily attributed to **rifaximin**, an antibiotic used to reduce ammoniagenic bacterial load.
*Promotion of ammonia excretion through increased renal clearance*
- The main effect of lactulose on ammonia clearance is through **gastrointestinal excretion** via the feces.
- It does not directly impact **renal function** or increase the kidneys' capacity for ammonia excretion.
Question 49: A 34-year-old woman presents with a 12-month history of crampy lower abdominal pain, abdominal distension, and loose stools up to 5 times daily. Symptoms are worse with stress and during menstruation. She has tried dietary modification without benefit. Examination and routine blood tests including coeliac serology are normal. She is diagnosed with IBS-D (diarrhoea predominant). First-line loperamide has provided minimal relief. What is the most appropriate pharmacological treatment?
A. Mebeverine 135 mg three times daily
B. Amitriptyline 10 mg at night, increased gradually (Correct Answer)
C. Linaclotide 290 mcg once daily
D. Eluxadoline 100 mg twice daily
E. Rifaximin 550 mg three times daily for 14 days
Explanation: ***Amitriptyline 10 mg at night, increased gradually***
- Low-dose **tricyclic antidepressants (TCAs)** are recommended as second-line treatment for **IBS-D** when first-line therapies like loperamide and dietary changes fail to control symptoms.
- TCAs act as **neuromodulators** to reduce **visceral hypersensitivity** and slow **gastrointestinal transit** time, effectively addressing both abdominal pain and loose stools.
*Mebeverine 135 mg three times daily*
- This is an **antispasmodic** typically used as **first-line therapy** for crampy pain in IBS; however, this patient has already failed first-line management.
- It does not address the **diarrhoea** or the global symptom complex as effectively as second-line pharmacological agents in this scenario.
*Linaclotide 290 mcg once daily*
- This is a **guanylate cyclase-C agonist** specifically licensed for **IBS with constipation (IBS-C)**, not the diarrhoea-predominant type.
- It increases **intestinal fluid secretion**, which would significantly worsen this patient's existing **loose stools**.
*Eluxadoline 100 mg twice daily*
- This is a **mixed opioid receptor modulator** used for IBS-D, but it is typically reserved for specialized use and is not routinely first-choice in UK primary care guidelines.
- It carries risks such as **pancreatitis** (especially in patients without a gallbladder) and is not as standard a second-line option as low-dose TCAs.
*Rifaximin 550 mg three times daily for 14 days*
- This is a **non-absorbable antibiotic** sometimes used to treat **bloating** and diarrhoea in IBS, possibly related to small intestinal bacterial overgrowth.
- It is not widely recommended as a standard second-line pharmacological treatment in general **NICE guidelines** compared to the established use of TCAs or SSRIs.
Question 50: A 45-year-old woman presents with burning retrosternal discomfort after meals and occasional regurgitation. She has been taking lansoprazole 30 mg daily for 3 months with minimal improvement. She has no dysphagia or weight loss. Upper GI endoscopy shows Los Angeles grade A oesophagitis and a 2 cm hiatus hernia. H. pylori rapid urease test is negative. What is the most appropriate next step in management?
A. Increase lansoprazole to 30 mg twice daily (Correct Answer)
B. Perform oesophageal manometry and 24-hour pH-impedance monitoring
C. Switch to a different proton pump inhibitor such as omeprazole
D. Add alginate therapy to current treatment
E. Refer for anti-reflux surgery
Explanation: ***Increase lansoprazole to 30 mg twice daily***- The patient has **confirmed gastro-oesophageal reflux disease (GORD)** with oesophagitis and persistent symptoms despite a standard once-daily PPI dose, indicating a need for more robust acid suppression.- **Doubling the dose** to **twice-daily lansoprazole** (taken 30-60 minutes before breakfast and dinner) is the most appropriate next step to optimize acid control and alleviate symptoms.
*Perform oesophageal manometry and 24-hour pH-impedance monitoring*- These **advanced diagnostic tests** are typically indicated for patients who remain symptomatic despite **optimized (twice-daily) PPI therapy** or when evaluating patients for potential surgical intervention.- It is premature to perform these investigations before adequately escalating and optimizing medical management.
*Switch to a different proton pump inhibitor such as omeprazole*- There is generally **limited evidence** to suggest that switching to a different PPI within the same class at an equivalent dose offers a significant advantage for refractory GORD.- **Dose optimization** of the current PPI is usually more effective than switching to another PPI at the same dose.
*Add alginate therapy to current treatment*- While alginates can provide **symptomatic relief** by forming a protective barrier, they do not address the underlying issue of persistent acid exposure causing oesophagitis.- They are typically used as **adjunctive therapy** for breakthrough symptoms rather than as a primary strategy for ongoing oesophagitis when PPI dosing can be optimized.
*Refer for anti-reflux surgery*- **Anti-reflux surgery** is considered for patients with GORD who have failed **maximal medical therapy** and have objective evidence of reflux confirmed by functional studies.- Since the patient has not yet received optimized medical therapy, surgical referral is premature.
